WHO advises that ivermectin only be used to treat COVID-19 within clinical trials (2021)

Government Record · World Health Organization · March 31, 2021

World Health Organization, 2021-03-31: WHO's statement that its guideline panel found the evidence on ivermectin for COVID-19 to be of very low certainty, so the drug should be used only inside clinical trials.

The group reviewed pooled data from 16 randomized controlled trials (total enrolled 2407), including both inpatients and outpatients with COVID-19.

World Health Organization, 2021-03-31: WHO's statement that its guideline panel found the evidence on ivermectin for COVID-19 to be of very low certainty, so the drug should be used only inside clinical trials. WHO news feature, published 31 March 2021 (datePublished in the page metadata). It records that the guideline development group reviewed pooled data from 16 randomized controlled trials (2407 participants) including inpatients and outpatients, and that the panel did not examine prophylaxis. The page's next sentence rates the evidence on mortality, ventilation, admission and clinical improvement as 'very low certainty'; that phrase is wrapped in quotation marks on the page and is therefore described here rather than spliced into the excerpt. Bearing CONTRADICTS. Study type: regulatory record.